Physician profile
Edward J Hepworth
NPI 1588766562
$8,666.38
in general payments reported to CMS, 2019-2025
38 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what 78% of Otolaryngic Allergy providers received nationally (typical 2025 total: $449).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $493 · 2021: $689 · 2022: $4,639 · 2023: $1,038 · 2024: $477 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,574 · Education: $86.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,574.46 |
| Education | $86.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $4,183.63 | 2020-2025 | Dupixent |
| Medtronic, INC. | $799.70 | 2021-2025 | Propel, Nuvent, Pteye Parathyroid Detection System |
| Genzyme Corporation | $588.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $488.32 | 2019-2025 | Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $451.99 | 2021-2025 | Nucala |
| Stryker Corporation | $259.07 | 2020-2022 | |
| Grifols USA, LLC | $251.15 | 2019-2023 | Prolastin-C Liquid, Xembify |
| Biocryst US Sales Co., LLC | $233.79 | 2025 | Orladeyo |
| Optinose US, INC. | $155.50 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $89.81 | 2021-2025 | |
| Csl Behring | $76.21 | 2019-2023 | Haegarda |
| Catalyst Pharmaceuticals, INC. | $72.53 | 2021-2023 | Firdapse |
| Takeda Pharmaceuticals U.S.A., INC. | $71.94 | 2021-2023 | Takhzyro |
| Shockwave Medical, INC | $67.55 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Acclarent, INC | $64.54 | 2020-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $59.54 | 2025 | Tezspire |
| Endo Pharmaceuticals INC. | $59.39 | 2020 | |
| Davol INC. | $58.37 | 2022-2023 | Progel Applicator Spray Tips |
| Acera Surgical, INC. | $56.12 | 2025 | Restrata Wound Matrix |
| Aerin Medical INC. | $53.41 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $52.99 | 2024 | |
| Phadia US INC. | $52.48 | 2023-2024 | Immunocap |
| Aroa Biosurgery Incorporated | $46.92 | 2024-2025 | |
| Ethicon US, LLC | $44.07 | 2019 | |
| Becton, Dickinson and Company | $38.83 | 2025 | |
| Karl Storz Endoscopy-America | $37.54 | 2020 | |
| Nestle Healthcare Nutrition INC. | $35.07 | 2021 | |
| Dilon Technologies, INC. | $32.95 | 2025 | Hemoblast Bellows |
| Biocryst Pharmaceuticals, INC. | $31.96 | 2020 | |
| Merck Sharp & Dohme LLC | $27.51 | 2021-2023 | |
| Smith+Nephew, INC. | $23.74 | 2019 | |
| Genentech USA, INC. | $20.96 | 2022 | |
| Medtronic USA, INC. | $20.36 | 2019 | |
| Octapharma USA, INC. | $19.26 | 2021 | |
| Cook Medical LLC | $15.24 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.86 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.85 | 2023 | Quviviq |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Hepworth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.